PTC Therapeutics (PTCT) said Thursday it has filed a new drug application with the US Food and Drug Administration for vatiquinone to treat children and adults with Friedreich's ataxia, a rare neuromuscular disorder.
The application is supported by data from the placebo-controlled MOVE-FA study and two long-term studies that show a "significant" reduction in disease progression and demonstrate a "safe and well-tolerated" vatiquinone across all age groups, the company said.
Price: 45.60, Change: +0.14, Percent Change: +0.31
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。